8-K: Applied Therapeutics Faces Nasdaq Delisting Warning After Share Price Drops Below $1

Applied Therapeutics received a notification from Nasdaq on February 7, 2025, indicating non-compliance with the minimum bid price requirement due to its stock price falling below $1.00 for 30 consecutive business days.

Summary

• Applied Therapeutics, Inc. received a notification from Nasdaq on February 7, 2025, stating that it no longer meets the minimum bid price requirement for continued listing on the Nasdaq Global Market.
• This is because the company's common stock closing bid price has been below $1.00 per share for 30 consecutive business days.
• The company has an initial compliance period until August 6, 2025, to regain compliance by having its stock price meet or exceed $1.00 per share for at least 10 consecutive business days.
• If compliance is not achieved by August 6, 2025, Applied Therapeutics may be eligible for an additional 180-day grace period if it transfers its listing to the Nasdaq Capital Market.
• The company intends to monitor its stock price and consider options to regain compliance, but no decisions have been made yet.
• There is no guarantee that Applied Therapeutics will regain compliance or maintain compliance with other Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting warning from Nasdaq, indicating financial challenges and potential risks for investors.

Negatives

• Applied Therapeutics is at risk of being delisted from the Nasdaq Global Market.
• The company's stock price has fallen below the required minimum of $1.00 per share for an extended period.

Risks

• There is no assurance that Applied Therapeutics will be able to regain compliance with the Nasdaq's minimum bid price requirement.
• Failure to regain compliance could result in delisting from the Nasdaq Global Market, which could negatively impact the company's stock price and investor confidence.
• The company's ability to raise capital may be hindered if it is delisted or transfers to the Nasdaq Capital Market.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider available options to regain compliance with the Bid Price Requirement, but no decisions about a response have been made at this time. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or will otherwise remain in compliance with other Nasdaq listing criteria.

Industry Context

Delisting warnings are not uncommon for companies facing financial difficulties or market downturns. The biotechnology sector, in particular, can be volatile, and companies with promising but yet-to-be-commercialized products are susceptible to stock price declines if clinical trials face setbacks or funding becomes scarce. Other companies in a similar situation include [Comparable Biotech Company 1] and [Comparable Biotech Company 2], which have also faced delisting warnings in the past due to low stock prices.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital may be affected.

Next Steps

• Applied Therapeutics will monitor its stock price.
• Applied Therapeutics will consider options to regain compliance with Nasdaq listing rules.

Key Dates